Targeted deletion of Interleukin-3 results in asthma exacerbations
Kölle J, Zimmermann T, Kiefer A, Rieker R, Xepapadaki P, Zundler S, Papadopoulos NG, Finotto S (2022)
Publication Type: Journal article
Publication year: 2022
Journal
Book Volume: 25
Article Number: 104440
Journal Issue: 6
DOI: 10.1016/j.isci.2022.104440
Abstract
The cytokine interleukin-3 (IL-3) acts on early hematopoietic precursor cells. In humans, Treg cells secrete IL-3 and repress inflammatory cells except for basophils. The present study aims to elucidate the contribution of IL-3 in the development and the course of allergic asthma. We therefore analyzed the secretion of IL-3 in PBMCs and total blood cells in two cohorts of pre-school children with and without asthma. In a murine model of allergic asthma, we analyzed the phenotype of IL-3−/− mice compared to wild-type mice. PBMCs from asthmatic children showed increased IL-3 secretion, which directly correlated with improved lung function. IL-3−/− asthmatic mice showed increased asthmatic traits. Moreover, IL-3-deficient mice had a defect in T regulatory cells in the lung. In conclusion, IL-3 downregulation was found associated with more severe allergic asthma in pre-school children. Consistently, targeting IL-3 resulted in an induced pathophysiological response in a murine model of allergic asthma.
Authors with CRIS profile
Involved external institutions
How to cite
APA:
Kölle, J., Zimmermann, T., Kiefer, A., Rieker, R., Xepapadaki, P., Zundler, S.,... Finotto, S. (2022). Targeted deletion of Interleukin-3 results in asthma exacerbations. iScience, 25(6). https://doi.org/10.1016/j.isci.2022.104440
MLA:
Kölle, Julia, et al. "Targeted deletion of Interleukin-3 results in asthma exacerbations." iScience 25.6 (2022).
BibTeX: Download